Quick Answer
CORCEPT THERAPEUTICS INC reported Research And Development Expense of $254.91 million for the year ending 2025.
- CORCEPT THERAPEUTICS INC showed an increase of +3.2% in Research And Development Expense from 2024 to 2025.
- This data is from CORCEPT THERAPEUTICS INC's annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $4.57 million | Q3 2010: $5.22 million | Q1 2011: $4.92 million | Q2 2011: $6.20 million | Q3 2011: $3.23 million | Q1 2012: $3.54 million | Q2 2012: $2.67 million | Q3 2012: $3.01 million | Q1 2013: $4.26 million | Q2 2013: $4.49 million | Q3 2013: $5.16 million | Q1 2014: $7.29 million | Q2 2014: $4.25 million | Q3 2014: $3.05 million | Q1 2015: $4.38 million | Q2 2015: $3.34 million | Q3 2015: $3.61 million | Q1 2016: $4.63 million | Q2 2016: $5.67 million | Q3 2016: $7.05 million | Q1 2017: $7.18 million | Q2 2017: $7.88 million | Q3 2017: $11.69 million | Q1 2018: $17.05 million | Q2 2018: $20.54 million | Q3 2018: $18.86 million | Q1 2019: $20.24 million | Q2 2019: $21.66 million | Q3 2019: $22.81 million | Q1 2020: $26.12 million | Q2 2020: $26.50 million | Q3 2020: $33.87 million | Q1 2021: $29.02 million | Q2 2021: $28.23 million | Q3 2021: $28.09 million | Q1 2022: $28.12 million | Q2 2022: $32.83 million | Q3 2022: $33.29 million | Q1 2023: $40.85 million | Q2 2023: $43.28 million | Q3 2023: $45.52 million | Q1 2024: $58.51 million | Q2 2024: $58.75 million | Q3 2024: $59.34 million | Q1 2025: $60.74 million | Q2 2025: $60.47 million | Q3 2025: $68.85 million.
- Over the full 17 years of available data (2009 to 2025), CORCEPT THERAPEUTICS INC's Research And Development Expense has grown by 1,669.9%.
- Historical annual values: Fiscal year 2025: $254.91 million | Fiscal year 2024: $246.89 million | Fiscal year 2023: $184.35 million | Fiscal year 2022: $130.99 million | Fiscal year 2021: $113.86 million | Fiscal year 2020: $114.76 million | Fiscal year 2019: $89.02 million | Fiscal year 2018: $75.25 million | Fiscal year 2017: $40.38 million | Fiscal year 2016: $23.84 million | Fiscal year 2015: $15.42 million | Fiscal year 2014: $18.37 million | Fiscal year 2013: $20.47 million | Fiscal year 2012: $14.07 million | Fiscal year 2011: $21.00 million | Fiscal year 2010: $18.95 million | Fiscal year 2009: $14.40 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: